GEN-MKT-18-7897-A
Oct 14, 2021 | Blogs, Environmental / Industrial | 0 comments
Read time: 2 minutes
Short-chain per- and polyfluoroalkyl substances (PFAS) are increasing in the Canadian Arctic environment, with the most rapid increases occurring post-2000, according to a recent study in Geophysical Research Letters (April 2020). For example, trifluoracetic acid (TFA) in the Devon Ice Cap increased ~10-fold from 1.4 μg/m2 per year during 1977–1989 to 10.3 μg/m2 per year during 2001–2014. The authors of the study suggest that the increased short-chain PFAS concentrations post-2000 were from new chlorofluorocarbon (CFC) replacement chemicals produced as a result of the 1987 Montreal Protocol treaty. One of the paper’s lead authors, Professor Cora Young of York University in Toronto, Ontario, discussed the study findings during the inaugural episode of my new video podcast, “PFAS fireside chats with Craig Butt.
PFAS are well-known environmental contaminants, and they are widely detected in surface and drinking water and in humans and wildlife. PFAS have many uses in commercial products due to their properties, such as stain repellency, and they are also used in firefighting foams to combat petroleum fires. The most widely known PFAS chemicals are perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA), which have 8 carbons. The chemicals examined in the study by Young et al. are similar to PFOA, but they have 2–4 carbons and are therefore known as short-chain PFAS. Chemicals from the fluoropolymer industry are typically attributed to long-chain PFAS, such as PFOA, that are found in remote environments. While these chemicals could explain the ice core concentrations of trifluoroacetic acid (TFA), which is 2 carbons, and perfluoropropanoic acid (PFPrA), which is 3 carbons, the study instead attributes their source to the degradation of CFC replacement chemicals, such as hydrochlorofluorocarbons (HCFCs) and hydrofluorocarbons (HFCs). These CFC replacements were manufactured to respond to the Montreal Protocol to combat ozone hole depletion. Therefore, international efforts to solve an environmental crisis may have unintentionally caused the global contamination of short-chain PFAS. While the study examined PFAS levels in the Canadian Arctic environment, Young believes that short-short-chain PFAS levels will be higher in more populated regions. However, due to their analytical difficulty, few labs are currently monitoring these “shorties,” which represents a major data gap. Also, while the human health implications are currently unknown, recent studies suggest that TFA may be more abundant in humans than previously thought.
Click here to read Prof. Cora and team’s full study.
*This content does not constitute legal advice. You should consult counsel to assure your procedures comply with applicable law and that it meets your needs.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network